Sign in Subscribe
Drug resistance

NeuroBlate Establishes LITT as Standard Surgical Option for Drug-Resistant Epilepsy

Strategic Insights

— 1 min read

NeuroBlate, a minimally invasive laser interstitial thermal therapy (LITT) system, has been proven effective in treating drug-resistant epilepsy, according to a landmark study published in JAMA Neurology. The study, which analyzed data from 145 patients across 15 U.S. institutions, demonstrates that LITT using NeuroBlate is a safe, durable, and minimally invasive surgical option for drug-resistant mesial temporal lobe epilepsy (MTLE). The results show that 58.4% and 57.2% of patients achieved Engel 1 and International League Against Epilepsy (ILAE) 1/2 seizure freedom classifications at one and two years, respectively. Patients also experienced short hospitalizations, low readmission rates, and positive recovery outcomes.

Key Takeaways:

  • The study, which included 145 patients across 15 U.S. institutions, represents the largest prospective analysis to date of LITT for drug-resistant epilepsy.
  • NeuroBlate achieved Engel 1 and ILAE 1/2 seizure freedom classifications in 58.4% and 57.2% of patients at one and two years, respectively.
  • Patients showed short hospitalizations, low readmission rates, and positive recovery outcomes, with nearly all discharged to their homes post-procedure.
  • The study highlighted the benefits of NeuroBlate, including reduced recovery time and minimally invasive technology.
  • Pediatric and adult patients showed comparable outcomes, confirming previously published evidence that LITT is a viable option for pediatric epilepsy.

Statistics:

  • 58.4% of patients achieved Engel 1 seizure freedom at one year.
  • 57.2% of patients achieved ILAE 1/2 seizure freedom classifications at two years.
  • 34.9% of patients either stopped or reduced their use of anti-seizure medications following the procedure.
  • Patients experienced an average of 5.6 days in the hospital, with 92% discharged to their homes post-procedure.

Sources:

  • Monteris Medical (2025) "NeuroBlate Demonstrates 58% Seizure Freedom at Two Years in Treatment of Drug-Resistant Epilepsy"
  • JAMA Neurology, "Laser Ablation for Drug-Resistant Epilepsy" (July 2025)
  • Monteris Medical, "LAANTERN Study Reveals Positive Outcomes for Patients with NeuroBlate"

Read more